Colgate-Palmolive Company

NYSE:CL

Household & Personal Products

Consumer Defensive
$98.85 -0.78%

-$0.71 today

Market cap
$78.58B
Beta
0.32
P/E (TTM)
34.5
EPS (TTM)
$2.60
Dividend yield
2.33%
52W Low $74.55High $99.33

Volume 6.07M

Average 5.62M

CL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Colgate-Palmolive CompanyNYSE: CL

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development remains negative

Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0. Over 3 fiscal years it compounded at +4.6% a year.

Context

  • Research & development amounted to 1.8% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$366M+3.1% YoY
LTMSep 2026
$0-100.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+3.1%——
3-year CAGR+4.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
366M USD
Year-over-year change
+3.1%
4-year CAGR
+4.5%

Research & Development vs competitors

How CL compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the 2nd highest of 3, against a peer median of -50.4%.
  • Research & development amounts to 0.0% of revenue for CL, versus a peer median of 0.0%.
CL Competitors
Research & Development for CL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KVUEKenvue Inc.LTM Sep 2026$180M USD——1.2%
CLXThe Clorox CompanyLTM Sep 2026$117M USD-0.8%-5.6%1.6%
CLColgate-Palmolive CompanyLTM Sep 2026$0 USD-100.0%+4.6%0.0%
PGThe Procter & Gamble CompanyLTM Sep 2026$0 USD——0.0%
ULUnilever PLCFY2025€0 EUR——0.0%
KMBKimberly-Clark CorporationLTM Jun 2026$0 USD-100.0%—0.0%
CHDChurch & Dwight Co., Inc.LTM Sep 2026$0 USD——0.0%
Peer median (excluding CL) —-50.4%-5.6%0.0%

Competitors are the stored peer set for CL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.42B17.97B19.46B20.1B20.38B
Cost of Revenue7.13B7.82B8.21B8B8.13B
Gross Profit10.29B10.15B11.25B12.11B12.25B
Gross Margin59.1%56.5%57.8%60.2%60.1%
Research & Development307M320M343M355M366M
Selling, General & Admin6.1B6.25B6.78B7.81B7.89B
Operating Expenses6.41B6.57B7.12B7.72B8.95B
Depreciation & Amortization556M545M567M605M630M
EBITDA3.76B3.37B4.25B4.85B4.87B
EBITDA Margin21.6%18.8%21.8%24.1%23.9%
Operating Income3.89B3.59B4.13B4.38B3.31B
Operating Margin22.3%20.0%21.2%21.8%16.2%
Interest Income17M14M55M67M75M
Interest Expense117M167M287M292M267M
Other Income / Expenses(799M)(925M)(739M)(427M)(247M)
Income Before Tax3.09B2.66B3.39B3.96B3.06B
Pre-Tax Margin17.7%14.8%17.4%19.7%15.0%
Income Tax Expense749M693M937M907M798M
Net Income2.17B1.79B2.3B2.89B2.13B
Net Margin12.4%9.9%11.8%14.4%10.5%
EPS (Basic)2.562.132.783.532.64
EPS (Diluted)2.552.132.773.512.63
Weighted Avg Shares845M836.4M827.4M817.7M808.7M
Weighted Avg Shares (Diluted)848.3M838.8M829.2M822.5M811.1M

Colgate-Palmolive Company

NYSE:CL

Intrinsic Alpha fair value

Locked

Current Price

$98.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.